Eli Lilly is a leader in one of today’s biggest growth markets: weight loss drugs. The company recently won approval for an ...

The Food and Drug Administration has recorded two ‘serious’ cases in patients taking Eli Lilly’s weight-loss pill.

Eli Lilly is coming off an impressive first-quarter performance, with sales soaring by 56%.

Eli Lilly (NYSE:LLY) just delivered one of the strongest first quarters in big pharma history, but shares have pulled back ...

Lilly hiked its full-year sales outlook by $2 billion, and also raised its adjusted profit guidance.

Mounjaro and Zepbound are driving Eli Lilly's earnings sharply higher. Foundayo looks like another top-seller. Eli Lilly's ...

As Eli Lilly gets off to the races with the launch of its flagship oral GLP-1 Foundayo, the Indianapolis drugmaker—and at ...

Needles are soon to be a thing of the past. Eli Lilly’s new GLP-1 drug, Foundayo, received approval from the Food and Drug ...